Genetic predisposition and hematopoietic malignancies in children: Primary immunodeficiency

It is assumed that patients with some forms of primary immunodeficiency (PID) have a markedly increased risk of cancer as compared to the healthy population. This increased incidence is seen in children as well as adult patients. The type of malignancy depends on the underlying genetic defect, but h...

Full description

Saved in:
Bibliographic Details
Published in:European journal of medical genetics Vol. 59; no. 12; pp. 647 - 653
Main Authors: van der Werff ten Bosch, Jutte, van den Akker, Machiel
Format: Journal Article
Language:English
Published: Netherlands Elsevier Masson SAS 01.12.2016
Subjects:
Child
Children
Genetic Predisposition to Disease
Hematologic Neoplasms - complications
Hematologic Neoplasms - epidemiology
Hematologic Neoplasms - genetics
Hematologic Neoplasms - pathology
Humans
Immunologic Deficiency Syndromes - complications
Immunologic Deficiency Syndromes - epidemiology
Immunologic Deficiency Syndromes - genetics
Immunologic Deficiency Syndromes - pathology
Leukemia
Lymphoma
Medical Education
Primary immuno deficiency
Risk Factors
Primary immuno deficiency
Children
Lymphoma
Leukemia
ISSN:1769-7212, 1878-0849, 1878-0849
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:It is assumed that patients with some forms of primary immunodeficiency (PID) have a markedly increased risk of cancer as compared to the healthy population. This increased incidence is seen in children as well as adult patients. The type of malignancy depends on the underlying genetic defect, but hematopoietic cancers are most frequent in almost any subtype of PID. In some patients, a malignancy can even be the first or only symptom of an underlying genetic defect. The possibility of an underlying PID is important for the pediatric oncologist as this might influence the treatment. Also, patients with a known PID should be screened for the occurrence of cancer. It is therefore important to raise awareness on this subject among clinicians involved in the treatment of children with cancer as well as in the treatment of children with PID.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1769-7212
1878-0849
1878-0849
DOI:10.1016/j.ejmg.2016.03.001